Regeneron, Halozyme, and Genmab Holdings in Healthcare ETFs
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Regeneron Pharmaceuticals is held within the State Street SPDR S&P Pharmaceuticals ETF. Halozyme Therapeutics and Genmab are held in the First Trust NYSE Arca Biotechnology Index Fund. Both funds track the healthcare sector.
From fool.com
Why it matters
The two funds offer different approaches to healthcare exposure; the SPDR ETF focuses on the pharmaceutical industry while the FBT fund concentrates on biotechnology. The SPDR fund has a lower expense ratio of 0.35% compared to the 0.55% charged by the First Trust fund.
From fool.com
Who's involved
- Regeneron PharmaceuticalsHeld within the State Street SPDR S&P Pharmaceuticals ETF
- Halozyme TherapeuticsHeld within the First Trust NYSE Arca Biotechnology Index Fund
- GenmabHeld within the First Trust NYSE Arca Biotechnology Index Fund
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Regeneron Pharmaceuticals
American pharmaceutical company
Nothing else this week.
-
Halozyme Therapeutics
Nothing else this week.
-
Genmab
Danish healthcare company